scholarly article | Q13442814 |
P50 | author | Daniel Haber | Q5217393 |
P2093 | author name string | Daphne W Bell | |
Jeffrey Settleman | |||
Raffaella Sordella | |||
P433 | issue | 5687 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lung cancer | Q47912 |
apoptotic process | Q14599311 | ||
P304 | page(s) | 1163-7 | |
P577 | publication date | 2004-08-20 | |
P1433 | published in | Science | Q192864 |
P1476 | title | Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | |
P478 | volume | 305 |
Q36883649 | "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?". |
Q36254754 | (Z)3,4,5,4'-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level. |
Q29998998 | 2004: Signaling Breakthroughs of the Year |
Q33937876 | 3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants |
Q36028935 | A Novel Technique to Detect EGFR Mutations in Lung Cancer. |
Q33994726 | A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance |
Q61444296 | A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer |
Q36488342 | A critical appraisal of prognostic and predictive factors for common lung cancers. |
Q34492884 | A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations |
Q92517460 | A novel bis-aryl urea compound inhibits tumor proliferation via cathepsin D-associated apoptosis |
Q36376408 | A review of erlotinib and its clinical use. |
Q42498384 | A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity |
Q92783310 | ADAM17: An Emerging Therapeutic Target for Lung Cancer |
Q36313197 | AKT crystal structure and AKT-specific inhibitors |
Q41201253 | AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells. |
Q39623714 | AXL regulates mesothelioma proliferation and invasiveness |
Q30931456 | Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. |
Q33947959 | Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. |
Q54561321 | Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. |
Q34626608 | Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors |
Q24816331 | Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R |
Q24794765 | Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain |
Q36910173 | Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants |
Q35971676 | Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury |
Q38494311 | Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. |
Q40176065 | Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation |
Q41471047 | Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC) |
Q36128435 | Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer |
Q33636907 | Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells |
Q34516556 | Adeno-associated virus vector mediated expression of an oncogenic retroviral envelope protein induces lung adenocarcinomas in immunocompetent mice |
Q41546742 | Akt Signaling Is Sustained by a CD44 Splice Isoform-Mediated Positive Feedback Loop |
Q39263992 | Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations |
Q24301372 | Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha |
Q41478504 | Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer |
Q36973814 | Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy |
Q36669872 | Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer |
Q37273963 | Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1. |
Q35578544 | Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway |
Q54124211 | Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis. |
Q33731181 | Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. |
Q24541450 | Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 |
Q88377651 | An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo |
Q53222808 | An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis. |
Q39009616 | An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma |
Q24293598 | An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor |
Q36493654 | An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family |
Q34407919 | An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs |
Q40200097 | An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer |
Q35058437 | Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases |
Q57763142 | Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas |
Q41612476 | Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification |
Q36466443 | Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm |
Q35480110 | Apoptosis-inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cells |
Q27016160 | Apoptotic agents |
Q36430311 | Applications of genomics in NSCLC. |
Q58712613 | Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer |
Q43061603 | Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors |
Q37052272 | Assessment of epidermal growth factor receptor status in glioblastomas |
Q28550377 | Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction |
Q37141943 | Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells |
Q26866067 | At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone |
Q36445905 | BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. |
Q50288616 | Binding of CBL to ligand-responsive p-6Y-EGFR mutants |
Q50288609 | Binding of GRB2:GAB1 complex to ligand-responsive p-6Y-EGFR mutants |
Q50288599 | Binding of GRB2:SOS1 complex to phosphorylated ligand-responsive EGFR mutants |
Q50288610 | Binding of PI3K to complex of GRB2:GAB1 and ligand-responsive p-6Y-EGFR mutants |
Q50288601 | Binding of SHC1 to p-6Y-EGFR mutants |
Q36540571 | Biological and clinical implications of EGFR mutations in lung cancer. |
Q37988924 | Biomarkers and transcriptome profiling of lung cancer |
Q36040606 | Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS |
Q34331327 | Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. |
Q92134610 | Brain metastases in oncogene-driven non-small cell lung cancer |
Q38840383 | Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. |
Q35196999 | Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth |
Q90370821 | CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development |
Q37051421 | CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment |
Q58802947 | Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling |
Q94348851 | Cancer Cell: Linking Oncogenic Signaling to Molecular Structure |
Q47386350 | Cancer stem cell-like population is preferentially suppressed by EGFR-TKIs in EGFR-mutated PC-9 tumor models |
Q36092823 | Carcinogenesis, cancer therapy and chemoprevention |
Q39205831 | Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. |
Q48283327 | Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC). |
Q34778365 | Characteristics of CD8+ T cell subsets in Chinese patients with chronic HIV infection during initial ART. |
Q48687589 | Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib |
Q91955116 | Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model |
Q38731759 | Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line. |
Q55369035 | Characterizing Cancer Drug Response and Biological Correlates: A Geometric Network Approach. |
Q37004639 | Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives |
Q33523195 | Chemosensitization of cancer cells by siRNA using targeted nanogel delivery |
Q52640291 | Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs. |
Q42109363 | Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. |
Q28077340 | Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? |
Q29615475 | Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers |
Q46815372 | Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer |
Q36111249 | Clinical applications for targeted therapy in bladder cancer |
Q46446185 | Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program |
Q44634377 | Clinical development of targeted moledular cancer drugs |
Q37220488 | Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer |
Q37334996 | Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis |
Q38041563 | Clinical testing for molecular targets for personalized treatment in lung cancer. |
Q80100938 | Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma |
Q33571227 | Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation |
Q33614314 | Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. |
Q41811594 | Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. |
Q33332189 | Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas |
Q37080964 | Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients |
Q54977986 | Combined caveolin-1 and epidermal growth factor receptor expression as a prognostic marker for breast cancer. |
Q50056486 | Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. |
Q38335360 | Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors |
Q34560075 | Comparing antibody and small-molecule therapies for cancer |
Q36882732 | Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. |
Q36865316 | Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS |
Q39378163 | Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. |
Q37657511 | Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients |
Q42066649 | Conditional deletion of Pten causes bronchiolar hyperplasia |
Q28386290 | Constitutive activation of epidermal growth factor receptor promotes tumorigenesis of Cr(VI)-transformed cells through decreased reactive oxygen species and apoptosis resistance development |
Q24302510 | Contribution of the orphan nuclear receptor Nur77 to the apoptotic action of IGFBP-3 |
Q52983736 | Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma. |
Q37109227 | Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. |
Q41606248 | Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer |
Q50288611 | Conversion of PIP2 to PIP3 by PI3K bound to ligand-responsive p-6Y-EGFR mutants |
Q37393014 | Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. |
Q36287463 | Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma |
Q46171346 | Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. |
Q92969824 | Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma |
Q46194088 | Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas |
Q33710152 | Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer |
Q37287006 | Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. |
Q36429474 | Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations |
Q36849663 | Current practices and guidelines for clinical next-generation sequencing oncology testing |
Q34637939 | Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme |
Q34283737 | Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours |
Q36284940 | Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy |
Q40135901 | Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. |
Q37690668 | Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma. |
Q38853191 | Delivery strategies and potential targets for siRNA in major cancer types |
Q34970672 | Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells |
Q54431224 | Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis. |
Q39437297 | Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction |
Q39531710 | Detection of low-level EGFR T790M mutation in lung cancer tissues |
Q40251398 | Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors |
Q39129178 | Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). |
Q90229878 | Development and Evaluation of Multifunctional Poly(Lactic-co-glycolic acid) Nanoparticles Embedded in Carboxymethyl β-Glucan Porous Microcapsules as a Novel Drug Delivery System for Gefitinib |
Q37630493 | Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer |
Q34000934 | Development of transcriptomic biomarker signature in human saliva to detect lung cancer |
Q33747930 | Diacylglycerol kinase delta and protein kinase C(alpha) modulate epidermal growth factor receptor abundance and degradation through ubiquitin-specific protease 8. |
Q38930336 | Diagnosis and Molecular Classification of Lung Cancer |
Q35434274 | Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors |
Q42131816 | Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations |
Q39781895 | Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors |
Q35540678 | Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer |
Q38889564 | Discovery of 2',4'-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC). |
Q58860040 | Discovery of dually acting small-molecule inhibitors of cancer-resistance relevant receptor tyrosine kinases EGFR and IGF-1R |
Q34701319 | Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation |
Q36547770 | Dissecting cancer pathways and vulnerabilities with RNAi |
Q51769749 | Dissecting cell signaling pathways with genetically encoded 3-iodo-L-tyrosine. |
Q50288615 | Dissociation of phosphorylated PLCG1 from ligand-responsive p-6Y-EGFR mutants |
Q42484909 | Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants |
Q58200558 | Divergent Synthesis of Quinazolines Using Organocatalytic Domino Strategies under Aerobic Conditions |
Q51214174 | Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. |
Q43191223 | Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells |
Q28471948 | Drosophila cbl is essential for control of cell death and cell differentiation during eye development |
Q36040613 | Drug resistance and its significance for treatment decisions in non-small-cell lung cancer |
Q28254233 | Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics |
Q63989113 | Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor |
Q28385103 | E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases |
Q29619032 | EGF-ERBB signalling: towards the systems level |
Q40235641 | EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer |
Q42513590 | EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair |
Q42701535 | EGFR T790M: revealing the secrets of a gatekeeper |
Q36048238 | EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort |
Q51340775 | EGFR exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patients. |
Q27851583 | EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer |
Q36306259 | EGFR inhibitors: what have we learned from the treatment of lung cancer? |
Q36758325 | EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy |
Q46717312 | EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. |
Q35164306 | EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry |
Q36844366 | EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment |
Q26852507 | EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer |
Q54538162 | EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: a meta-analysis. |
Q35800614 | EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. |
Q46677125 | EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids |
Q39362508 | EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer |
Q39538057 | EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride |
Q36026188 | EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway |
Q39106976 | EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity |
Q51040009 | EGFR-mediated apoptosis via STAT3. |
Q34356008 | EGFs and ERBBs—Brief history and prospects |
Q27851440 | EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer |
Q38805633 | EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer |
Q29619520 | ERBB receptors and cancer: the complexity of targeted inhibitors |
Q38919117 | ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas |
Q37153622 | ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer |
Q52649612 | ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells. |
Q37661108 | ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition |
Q33727478 | Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line |
Q42660638 | Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer |
Q55012925 | Effects of general anesthesia with or without epidural block on tumor metastasis and mechanisms. |
Q39515313 | Effects of respiratory mechanical forces on the pharmacological response of lung cancer cells to chemotherapeutic agents |
Q37691441 | Emerging MEK inhibitors. |
Q42869980 | Endocytosis and cancer |
Q34606927 | Enhanced T cell lymphoma in NOD.Stat5b transgenic mice is caused by hyperactivation of Stat5b in CD8+ thymocytes |
Q38798148 | Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells |
Q54531321 | EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex. |
Q88776744 | Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective ob |
Q36458742 | Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy |
Q39828582 | Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer |
Q54361563 | Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC). |
Q42818168 | Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations |
Q35793804 | Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone |
Q46371923 | Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy |
Q44485092 | Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer |
Q34557318 | Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer |
Q44051250 | Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma |
Q37634598 | Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer |
Q35013457 | Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy |
Q36504349 | Epidermal growth factor receptor inhibition and non-small cell lung cancer |
Q64234550 | Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice |
Q36429442 | Epidermal growth factor receptor inhibitors in cancer treatment. |
Q36830108 | Epidermal growth factor receptor inhibitors in non-small cell lung cancer |
Q37252270 | Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas |
Q29615474 | Epidermal growth factor receptor mutations in lung cancer |
Q36817294 | Epidermal growth factor receptor mutations in lung cancers. |
Q39918647 | Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling |
Q39752055 | Epidermal growth factor receptor signaling in nonsmall cell lung cancer |
Q34561698 | Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway |
Q36850793 | Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. |
Q36493232 | Epidermal growth factor receptor-targeted agents for lung cancer |
Q33779882 | Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized |
Q36674536 | Epidermal growth factor regulates hematopoietic regeneration after radiation injury |
Q28084034 | Epidermal growth factor signaling in transformed cells |
Q36042698 | Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer. |
Q38714404 | Epigallocatechin-3-gallate augments the therapeutic effects of benzo[a]pyrene-mediated lung carcinogenesis |
Q38150749 | Epistatic interactions and drug response |
Q24535592 | Epithelial membrane protein-1 is a biomarker of gefitinib resistance. |
Q37977436 | Epithelial mesenchymal transition and lung cancer |
Q38729111 | ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology |
Q33928631 | ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines |
Q37249978 | ErbBs in lung cancer |
Q40251565 | Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial |
Q58615775 | Essential roles of mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis |
Q37728841 | Establishment and characterization of primary lung cancer cell lines from Chinese population |
Q37399540 | Ethnic differences and functional analysis of MET mutations in lung cancer |
Q40018113 | Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. |
Q37589516 | Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists |
Q29615120 | Exploiting the PI3K/AKT pathway for cancer drug discovery |
Q37818230 | Exploration of synthetic lethal interactions as cancer drug targets |
Q54388141 | Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution. |
Q49887971 | Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. |
Q33684453 | Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer |
Q28252845 | Factors underlying sensitivity of cancers to small-molecule kinase inhibitors |
Q26830811 | From modules to medicine: How modular domains and their associated networks can enable personalized medicine |
Q36457037 | From the bench to the bed: individualizing treatment in non-small-cell lung cancer |
Q36120023 | Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain |
Q54977360 | Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR. |
Q37040827 | Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer |
Q40161268 | Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib |
Q80100963 | Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study |
Q28485309 | Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa |
Q37290533 | Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma. |
Q40418546 | Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). |
Q36161284 | Gefitinib in non-small cell lung cancer |
Q36610166 | Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). |
Q34447234 | Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells |
Q39054011 | Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells |
Q30544631 | Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study |
Q45169148 | Gefitinib--a novel targeted approach to treating cancer |
Q28469345 | Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics |
Q35580846 | Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells |
Q33207883 | Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer |
Q30988680 | Gene set analysis exploiting the topology of a pathway. |
Q36393012 | Genetic alterations in urothelial bladder carcinoma: an updated review |
Q37113682 | Genetic predictors of MEK dependence in non-small cell lung cancer |
Q33313648 | Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers |
Q36195093 | Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer |
Q27851633 | Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors |
Q37699199 | Gli1 promotes colorectal cancer metastasis in a Foxm1-dependent manner by activating EMT and PI3K-AKT signaling |
Q80051640 | Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? |
Q37828397 | Glutaminase: a hot spot for regulation of cancer cell metabolism? |
Q90429716 | Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M |
Q34908845 | Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer. |
Q33699007 | HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation |
Q36615002 | HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients |
Q38615197 | HER3/ErbB3, an emerging cancer therapeutic target |
Q36249234 | Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer |
Q33336861 | High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies |
Q51753083 | Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. |
Q37068513 | Highly parallel identification of essential genes in cancer cells |
Q38858961 | Honokiol targets mitochondria to halt cancer progression and metastasis |
Q37588365 | How and when to use genetic markers for nonsmall cell lung cancer. |
Q36429550 | How will lung cancer be treated in the future? |
Q37772399 | Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. |
Q39960713 | Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance |
Q40352167 | Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines |
Q64058267 | Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells |
Q30877356 | Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells |
Q28548412 | Identification of Biomarker and Co-Regulatory Motifs in Lung Adenocarcinoma Based on Differential Interactions |
Q39707468 | Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib |
Q28477481 | Identification of potent EGFR inhibitors from TCM Database@Taiwan |
Q46557776 | Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck |
Q36127636 | Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics |
Q58582701 | Identifying EGFR-Expressed Cells and Detecting EGFR Multi-Mutations at Single-Cell Level by Microfluidic Chip |
Q35264584 | Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET. |
Q38420747 | Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics. |
Q36423688 | Immunogenetic programs for viral induction of mucous cell metaplasia |
Q51046274 | Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma. |
Q39712642 | Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations |
Q39701114 | In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. |
Q54379896 | In vivo activation of the PI3K-Akt pathway in mouse beta cells by the EGFR mutation L858R protects against diabetes. |
Q60921926 | Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression |
Q33686369 | Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway |
Q36082004 | Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms |
Q36026392 | Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas |
Q46782213 | Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. |
Q37602377 | Inhibiting PI3K as a therapeutic strategy against cancer |
Q35928707 | Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth |
Q36795358 | Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer |
Q33227206 | Inhibition of EGFR signaling: all mutations are not created equal |
Q33571026 | Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel |
Q38866417 | Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells |
Q37460333 | Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy |
Q34581860 | Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo |
Q92134225 | Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S |
Q24301761 | Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface |
Q53794752 | Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer. |
Q33401214 | Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data |
Q27725743 | Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR |
Q40440883 | Insulin-activated, K+-channel-sensitive Akt pathway is primary mediator of ML-1 cell proliferation |
Q55055524 | Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer. |
Q38364439 | Intracellular signals of lung cancer cells as possible therapeutic targets |
Q35994416 | Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition |
Q33700689 | Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis? |
Q24603941 | Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells |
Q35474544 | Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling |
Q37512570 | Investigational agents in the management of non-small cell lung cancer. |
Q38323440 | Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. |
Q33821320 | Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib |
Q39328532 | JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation |
Q53608822 | Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. |
Q80202684 | KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance |
Q53242395 | KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer. |
Q21563446 | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib |
Q46555496 | Killing time for cancer cells |
Q54978633 | Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest. |
Q46965909 | Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer |
Q36640684 | Laricitrin suppresses increased benzo(a)pyrene-induced lung tumor-associated monocyte-derived dendritic cell cancer progression |
Q33358603 | Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type |
Q48231295 | Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer. |
Q35566222 | Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression |
Q37488529 | Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells |
Q39642171 | Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations |
Q37438296 | Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers |
Q34666826 | Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors |
Q64086539 | Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach |
Q34541960 | Lung cancer therapeutics that target signaling pathways: an update |
Q39741320 | Lung cancers unrelated to smoking: characterized by single oncogene addiction? |
Q24309725 | Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells |
Q36265149 | MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition |
Q54166640 | Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. |
Q90300758 | Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer |
Q27679902 | Mechanism for activation of mutated epidermal growth factor receptors in lung cancer |
Q42043613 | Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients |
Q50146512 | Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. |
Q36559283 | Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy |
Q41918077 | Mechanisms of human cytomegalovirus infection with a focus on epidermal growth factor receptor interactions |
Q37766260 | Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy |
Q38683133 | Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases |
Q35844565 | Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway |
Q37274389 | MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers |
Q33527586 | MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol |
Q64875418 | MicroRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy |
Q39890068 | Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase |
Q28484612 | Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression |
Q26771116 | Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer |
Q36612550 | Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. |
Q24606677 | Molecular biology of lung cancer |
Q24610335 | Molecular biology of lung cancer: clinical implications |
Q33969308 | Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study |
Q34778891 | Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project |
Q42822469 | Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases |
Q48451660 | Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. |
Q37061902 | Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA |
Q38060727 | Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors |
Q37602884 | Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype |
Q27691299 | Molecular pathology of lung cancer: key to personalized medicine |
Q36772562 | Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer |
Q36498832 | Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer |
Q33609045 | Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing |
Q36547758 | Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors |
Q26824599 | Molecular testing in lung cancer in the era of precision medicine |
Q35854276 | Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma |
Q39455567 | Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients |
Q36936796 | Multimodality imaging of the HER-kinase axis in cancer |
Q39246320 | Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer |
Q33915992 | Multiple roles and therapeutic implications of Akt signaling in cancer. |
Q35106771 | Multiscale computational models in physical systems biology of intracellular trafficking |
Q38816286 | Mutant Proteogenomics |
Q52642806 | Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis. |
Q40149065 | Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. |
Q40237141 | Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients |
Q36824808 | Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis |
Q54671910 | Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. |
Q24669579 | Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas |
Q35551048 | Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking |
Q35380919 | N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells |
Q36508097 | New and emerging radiosensitizers and radioprotectors |
Q42024692 | New targets and challenges in the molecular therapeutics of cancer |
Q34657670 | Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. |
Q54948216 | Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. |
Q47146342 | Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3. |
Q28278682 | Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship |
Q37692660 | Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain |
Q35063410 | Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells |
Q90349512 | Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors |
Q33569458 | Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells |
Q35623817 | Oncogenes come of age. |
Q36762385 | Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment |
Q33902463 | Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation |
Q34323807 | Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases |
Q24810573 | Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants |
Q38520010 | Opportunities and challenges in using studies without a control group in comparative effectiveness reviews |
Q37697442 | Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site |
Q24678516 | Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation |
Q35763328 | Overview of the development of personalized genomic medicine and surgery |
Q58091925 | Oxytetracycline have the therapeutic efficiency in CD133 HCC population through suppression CD133 expression by decreasing of protein stability of CD133 |
Q55012187 | PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. |
Q55256271 | PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer. |
Q33870342 | PIK3CA mutations and copy number gains in human lung cancers |
Q39826662 | PKC-delta binds to E-cadherin and mediates EGF-induced cell scattering |
Q92669056 | PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation |
Q50288612 | PLCG1 binds to ligand-responsive p-6Y-EGFR mutants |
Q36187706 | PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2. |
Q44846498 | PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. |
Q35653997 | PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy |
Q42944759 | PUMA Kills Stem Cells to Stall Cancer? |
Q34300057 | PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01. |
Q33857728 | PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells |
Q38831311 | Panaxydol, a component of Panax ginseng, induces apoptosis in cancer cells through EGFR activation and ER stress and inhibits tumor growth in mouse models |
Q37398845 | Parameters for individualizing systemic therapy in non-small cell lung cancer |
Q35584647 | Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects |
Q28657698 | Pathway analysis for drug repositioning based on public database mining |
Q34781357 | Pathways driving the endocytosis of mutant and wild-type EGFR in cancer |
Q61451510 | Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancer |
Q36117926 | Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. |
Q28586781 | Personalized characterization of diseases using sample-specific networks |
Q36817080 | Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer |
Q57177486 | Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective |
Q37412844 | Perspectives in mammalian IGFBP-3 biology: local vs. systemic action |
Q24339394 | Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms |
Q36313181 | Perturbations of the AKT signaling pathway in human cancer |
Q34042708 | Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity |
Q28278381 | Pharmacodynamic biomarkers for molecular cancer therapeutics |
Q38262008 | Pharmacogenomic biomarkers for personalized cancer treatment. |
Q36966043 | Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies |
Q56446183 | Pharmacogenomics steps toward personalized medicine |
Q38803038 | Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics |
Q36219744 | Phosphoproteomics for oncology discovery and treatment |
Q27851872 | Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR |
Q36632245 | Point mutations of protein kinases and individualised cancer therapy |
Q40213093 | Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. |
Q39049572 | Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer |
Q26863474 | Preclinical Murine Models for Lung Cancer: Clinical Trial Applications |
Q36547786 | Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors |
Q38390126 | Predicting resistance by selection of signaling pathways |
Q40053178 | Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics |
Q45116933 | Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). |
Q57896476 | Predictive Tumor Biomarkers for EGFR Inhibitors |
Q35076206 | Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer |
Q39640248 | Predictive biomarkers in the management of EGFR mutant lung cancer |
Q35875753 | Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer |
Q37799825 | Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer |
Q27852993 | Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients |
Q37996270 | Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer |
Q54632156 | Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. |
Q64235237 | Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis |
Q90087574 | Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer |
Q38187627 | Prognostic value of phospho-Akt in patients with non-small cell lung carcinoma: a meta-analysis |
Q35632548 | Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials |
Q36235591 | Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity |
Q36337922 | Prospects of RNA interference therapy for cancer |
Q38759724 | Protein Kinase G facilitates EGFR-mediated cell death in MDA-MB-468 cells |
Q35203134 | Protein domain-level landscape of cancer-type-specific somatic mutations |
Q39976000 | Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors |
Q36463998 | Protein kinases and phosphatases as therapeutic targets in cancer. |
Q36969009 | Proteins, drug targets and the mechanisms they control: the simple truth about complex networks |
Q42096010 | Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR. |
Q28540324 | QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR |
Q37330722 | Quantitative modeling perspectives on the ErbB system of cell regulatory processes |
Q37302721 | Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors |
Q37340472 | Quantitative prediction of fold resistance for inhibitors of EGFR. |
Q37649220 | Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition |
Q35051834 | RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer |
Q34138262 | RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy? |
Q57293866 | RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer Therapeutics |
Q35934254 | RNAi and HTS: exploring cancer by systematic loss-of-function |
Q42700759 | RPN2 promotes colorectal cancer cell proliferation through modulating the glycosylation status of EGFR |
Q33873095 | Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer |
Q33948614 | Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. |
Q35789960 | Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas |
Q42204869 | Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine |
Q46486238 | Rationale for combination use of targeted agents in ovarian cancer: do we have one? |
Q36318531 | Recent advances in targeted therapy of human myelogenous leukaemia |
Q36491838 | Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain |
Q21092930 | Recent advances of novel targeted therapy in non-small cell lung cancer |
Q38023942 | Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. |
Q43095950 | Reconstruction of an integrated genome-scale co-expression network reveals key modules involved in lung adenocarcinoma |
Q33838524 | Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. |
Q54561641 | Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. |
Q35166782 | Renal cell carcinoma and the use of sorafenib |
Q24658420 | Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses |
Q38256553 | Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma |
Q55178886 | Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification. |
Q46941491 | Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor |
Q33576476 | Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. |
Q36225230 | Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha |
Q44843905 | Restriction endonuclease-mediated real-time digestion-PCR for somatic mutation detection |
Q37093554 | Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population |
Q35584486 | Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer |
Q54340378 | Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. |
Q37331465 | Role of apoptosis in colon cancer biology, therapy, and prevention |
Q34417886 | Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer |
Q53687949 | Role of long non-coding RNA in drug resistance in non-small cell lung cancer. |
Q33576845 | Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer |
Q50288600 | SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with ligand-responsive p-6Y-EGFR mutants) |
Q50288606 | SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and ligand-responsive p-6Y-EGFR mutants) |
Q53058056 | Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms. |
Q38829545 | Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib |
Q58151801 | Selective Energy Transfer Between Quantum Dots and Gold Nanoparticles for Detection of Multiple Mutations in Epidermal Growth Factor Receptor |
Q36616873 | Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib |
Q45058705 | Selective targeting of point-mutated KRAS through artificial microRNAs |
Q41483948 | Sensitive genotyping of mutations in the EGFR gene from NSCLC patients using PCR-GoldMag lateral flow device. |
Q37468539 | Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies |
Q34274373 | Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. |
Q37378176 | Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung |
Q46946875 | Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas |
Q44715034 | Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience |
Q35176147 | Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer |
Q35987785 | Signaling multiplex of the epidermal growth factor receptor |
Q36392991 | Signaling networks assembled by oncogenic EGFR and c-Met |
Q54964048 | Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor and PTEN Genes. |
Q36395322 | Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor. |
Q40230093 | Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma |
Q37638679 | Small-molecule inhibitors of the human epidermal receptor family. |
Q34704519 | SmgGDS regulates cell proliferation, migration, and NF-kappaB transcriptional activity in non-small cell lung carcinoma |
Q36895457 | Smoking and lung cancer: future research directions |
Q37502708 | Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. |
Q24648133 | Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer |
Q37235024 | Somatic pharmacogenomics in cancer |
Q93083893 | Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer |
Q64890079 | Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer. |
Q38674296 | Stem Cell Therapy for Interstitial Cystitis/Bladder Pain Syndrome |
Q41942436 | Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme |
Q37840092 | Strategies for tumor-directed delivery of siRNA. |
Q35968384 | Strategies to overcome resistance to targeted protein kinase inhibitors |
Q38525856 | Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer |
Q35017477 | Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay |
Q33810641 | Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer |
Q39025002 | Structural bioinformatics-based identification of EGFR inhibitor gefitinib as a putative lead compound for BACE. |
Q90179057 | Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation |
Q37122918 | Structure and clinical relevance of the epidermal growth factor receptor in human cancer |
Q27644014 | Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity |
Q35673332 | Sulforaphane attenuates EGFR signaling in NSCLC cells |
Q37699402 | Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice |
Q36311791 | Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis |
Q37227994 | Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy |
Q34635475 | Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib |
Q39429719 | Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo |
Q38897130 | Synthesis, reactivity, and biological activity of gold(I) complexes modified with thiourea-functionalized tyrosine kinase inhibitors |
Q33587012 | Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery |
Q37214774 | Systematic discovery of complex insertions and deletions in human cancers. |
Q38194591 | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond |
Q38264440 | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond |
Q92993100 | TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations |
Q42582783 | Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation |
Q36920799 | Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives |
Q35953128 | Targeted cancer therapy |
Q36786085 | Targeted cancer therapy: promise and reality |
Q36054970 | Targeted therapies for lung cancer: clinical experience and novel agents |
Q37956110 | Targeted therapies: how personal should we go? |
Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications. |
Q37293656 | Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma |
Q37410635 | Targeting SOD1 reduces experimental non–small-cell lung cancer |
Q36580144 | Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation |
Q90481579 | Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors |
Q36804444 | Targeting signal transduction in pancreatic cancer treatment |
Q91620717 | Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update |
Q37741531 | Targeting the Mammalian Target of Rapamycin in Lung Cancer. |
Q36742629 | Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations |
Q34205052 | Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. |
Q41825773 | Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. |
Q36077604 | Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib. |
Q27010154 | The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics |
Q38166599 | The Biological Role of PI3K Pathway in Lung Cancer |
Q49887941 | The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells. |
Q54498075 | The ERBB network: at last, cancer therapy meets systems biology. |
Q37135372 | The ERBB3 receptor in cancer and cancer gene therapy |
Q34558080 | The HER family and cancer: emerging molecular mechanisms and therapeutic targets |
Q37716667 | The Hippo signaling pathway provides novel anti-cancer drug targets |
Q35078950 | The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects |
Q58694197 | The Network of Non-coding RNAs in Cancer Drug Resistance |
Q52880165 | The Role of Dysregulated MicroRNA Expression in Lung Cancer. |
Q38199934 | The Role of STAT3 in Non-Small Cell Lung Cancer |
Q24649549 | The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP |
Q37709481 | The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations |
Q28268061 | The concept of synthetic lethality in the context of anticancer therapy |
Q37077933 | The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations |
Q39353140 | The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor |
Q26753387 | The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations |
Q47138128 | The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations. |
Q35076292 | The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations |
Q40323538 | The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events |
Q36268324 | The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? |
Q37839576 | The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer |
Q40399733 | The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity |
Q37098747 | The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties |
Q36303828 | The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy |
Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
Q40169126 | The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. |
Q92534345 | The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
Q35133782 | The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation |
Q36219713 | The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. |
Q37724259 | The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer |
Q35167981 | The proliferative effects of Pyropia yezoensis peptide on IEC-6 cells are mediated through the epidermal growth factor receptor signaling pathway |
Q36704645 | The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics |
Q24616659 | The role of Src in solid tumors |
Q42095201 | The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants |
Q33779663 | The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer |
Q36274952 | The survival kinases Akt and Pim as potential pharmacological targets |
Q96231168 | The top 100 cited articles in lung cancer - a bibliometric analysis |
Q54940651 | The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer. |
Q37755154 | Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates |
Q34061302 | Therapeutic potential of targeting the oncogenic SHP2 phosphatase |
Q37690755 | Therapeutic targeting of EGFR in malignant gliomas |
Q92134589 | Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer |
Q39290667 | Threonine 2609 phosphorylation of the DNA-dependent protein kinase is a critical prerequisite for epidermal growth factor receptor-mediated radiation resistance |
Q36050719 | Throwing new light on lung cancer pathogenesis: updates on three recent topics |
Q36141341 | Tissue biomarkers for prostate cancer radiation therapy |
Q64279348 | Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498 |
Q50288598 | Trans-autophosphorylation of activated ligand-responsive EGFR mutant dimers |
Q33306709 | Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations |
Q37448428 | Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis |
Q39976030 | Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene |
Q46590868 | Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology |
Q37894095 | Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive |
Q48128121 | Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. |
Q37431491 | Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics |
Q36173303 | Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer |
Q34474427 | Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer. |
Q35602598 | Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib |
Q47893937 | Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients |
Q54325987 | What new therapeutic targets exist for EGFR-mutant NSCLC? |
Q37202390 | Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling. |
Q33870872 | ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain |
Q84170796 | [Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer] |
Q54548364 | [Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation]. |
Q54584669 | [Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy]. |
Q91807615 | microRNAs Tune Oxidative Stress in Cancer Therapeutic Tolerance and Resistance |
Q39373570 | p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway |
Q53355086 | ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. |
Q46707269 | siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma |
Q41592800 | siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells |
Search more.